Amit Barua, Joseph Hubble, Kathryn Yoo, Michael Lacassagne, John P. Areno, Louis Trachtman and Juzar Ali*

Department of Health, Office of Public Health, Tuberculosis Control, Louisiana, USA

*Corresponding Author: Juzar Ali, LSUHSC, & Office of Public Health, Tuberculosis Control, Louisiana, USA.

Received: June 09, 2021; Published: August 16, 2021

Citation: Michael Lacassagne and Juzar Ali. "Recurrent Pulmonary Tuberculosis in Low Prevalence Settings: Case Report from Louisiana". Acta Scientific Microbiology 5.9 (2021): 71-74.

Abstract

  Recurrence of Pulmonary tuberculosis (TB) after successful completion of supervised treatment may be due to relapse or reinfection. Recurrence is common with an incidence rate of 2.26 per 100 person years over a mean follow up of 2.3 years. However, it is uncommon for an immunocompetent individual to experience multiple episodes of recurrences. We describe a 67yo, Human Immunodeficiency Virus (HIV) seronegative man, seen in the public health system in Louisiana, USA with multiple relapses of TB due to drug susceptible MTB despite successful completion of guideline based direct observed treatment regimen in each episode. This case report highlights the need for increased awareness and recognition of risk factors contributing to the recurrence of TB even in countries with low prevalence of TB. Better understanding of the importance of drug penetration and action on varying mycobacterial populations within diseased lung tissue would also aid clinicians in the management of these relapses.

Keywords: Recurrent Tuberculosis; Pulmonary Tuberculosis; Relapse; Low TB Prevalence Area

Bibliography

1. Genotyping | Data and Statistics | TB | CDC (2021).
2. Vega V., et al. “Recurrent TB: a systematic review and meta-analysis of the incidence rates and the proportions of relapses and reinfections”. Thorax5 (2021): 494-502.
3. Kim L., et al. “Epidemiology of recurrent tuberculosis in the United States, 1993-2010”. International Journal of Tuberculosis and Lung Disease 3 (2013): 357-360.
4. Jasmer RM., et al. “Recurrent Tuberculosis in the United States and Canada”. American Journal of Respiratory and Critical Care Medicine 12 (2004): 1360-1366.
5. Rosser A., et al. “Recurrent tuberculosis in the pre-elimination era”. International Journal of Tuberculosis and Lung Disease2 (2018): 139-150.
6. Wang EY., et al. “The impact of smoking on tuberculosis treatment outcomes: a meta-analysis”. International Journal of Tuberculosis and Lung Disease 2 (2020): 170-175.
7. Farazi A and Jabbariasl M. “Silico-tuberculosis and associated risk factors in central province of Iran”. Pan African Medical Journal 20 (2015).
8. Lambert M-L., et al. “Recurrence in tuberculosis: relapse or reinfection?” Lancet Infectious Disease5 (2003): 282-287.
9. Cox H., et al. “Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance”. PLoS Medicine10 (2006): 384.
10. Nahid P., et al. “Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis”. Clinical Infectious Disease7 (2016): e147-e195.
11. Xu Y., et al. “Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes”. Annals of Clinical Microbiology and Antimicrobials 16 (2017).
12. Meylan S., et al. “Targeting Antibiotic Tolerance, Pathogen by Pathogen”. Cell6 (2018): 1228-1238.
13. Mitchison DA. “Basic Mechanisms of Chemotherapy”. Chest6 (1979): 771-780.
14. Steingart KR., et al. “Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review”. International Journal of Tuberculosis and Lung Disease3 (2011): 305-316.
15. de Steenwinkel JEM., et al. “Time–kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis”. Journal of Antimicrobial Chemotherapy 12 (2010): 2582-2589.

Copyright: © 2021 Amit Barua., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.